Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
Earlier this year, the FDA announced plans to launch Project FrontRunner to support manufacturers in prioritizing the development of cancer drugs in early treatment lines, partly in response to issues that have arisen with the current accelerated approval scheme. In this #Access90 video, Precision's Dominika Meszarosova discusses the issues that Project Frontrunner seeks to address and the critical need for early dialogue, incentives and close collaboration with manufacturers to ensure success.
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
In this new downloadable brief, PRECISIONadvisors experts Katherine Leong and David Carr provide a quick overview of the current digital therapeutics landscape in Europe, taking a closer look at the rapidly-expanding list of interventions as well as the varied ways that EU countries are approaching policy, regulation and reimbursement.
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
